| genes mutated in ovarian clear cell carcinoma(OCCC);data suggest PPP2R1A functions as an oncogene and ARID1A as tumor-suppressor gene; in 42 OCCCs, 7% had mutations in PPP2R1A and 57% in ARID1A; suggests aberrant chromatin remodeling contributes to OCCC | ovarian, |
| Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. | ovarian, |
| PPP2R1A mutations affect PP2A function and oncogenic signaling, illuminating the genetic basis for serous EC development. | None |
| R183W mutant of PPP2R1A, the gene encoding the PP2A Aalpha scaffolding subunit, failed to suppress tumor growth in vivo through activation of the MAPK pathway in RAS-mutant transformed cells. Cells expressing R183W were less sensitive to MEK inhibitors. Results demonstrate that the R183W mutation in PPP2R1A potentiates oncogenic signaling and reduces drug sensitivity of RAS-mutant cells to MEK inhibitors. | None |